Literature DB >> 8868982

Changing from intensive anticoagulation to treatment with aspirin alone for coronary stents: the experience of one centre in the United Kingdom.

N G Stephens1, P F Ludman, M C Petch, P M Schofield, L M Shapiro.   

Abstract

OBJECTIVE: To investigate whether an elective change in the anticoagulation protocol for patients with coronary stents affected clinical outcomes and length of hospital stay.
DESIGN: Retrospective observational study of a consecutive series of patients treated with coronary stents over an 18 month period from April 1994 to October 1995.
BACKGROUND: Intensive anticoagulation regimens are used in many UK centres to reduce the risk of coronary stent thrombosis. Recent data have called into question the necessity for full anticoagulation and favourable results have been reported with antiplatelet agents alone. The results from a tertiary referral centre were investigated during a period where an elective change in policy was made: an initial 70 patients were treated intensively with intravenous heparin and with warfarin and aspirin; subsequently 94 were treated with aspirin and deployment of a high pressure balloon only.
METHODS: Review of case notes, angiograms, and a database of intervention procedures and telephone interview. Classic epidemiological techniques, as well as linear regression and logistic regression, were used to model the outcomes of major procedural complications and length of hospital stay. PATIENTS: 164 patients treated with 196 coronary stents.
RESULTS: There were 22 (13.4%) major complications (coronary bypass grafting 11, subacute thrombosis 6, tamponade 2, myocardial infarction 1, death 2). With logistic regression, the risk of major complication was shown not to be affected by anticoagulation (relative risk (RR) 1.03; P = 0.97). Significant determinants of risk included acute vessel closure as an indication for stenting (RR = 80.6; P < 0.001) and sex (male: female RR = 0.19; P = 0.02). The median length of stay (LOS) was 5 days (1-45). Use of a linear regression model showed that anticoagulation added 4.5 days and a major complication added a further 4.5 days to a baseline length of stay of 3.2 days (R2 = 0.32; P < 0.001).
CONCLUSION: This is a report of coronary stenting as part of usual clinical practice in one British tertiary referral centre. In this experience, treatment with aspirin alone is probably as safe as intensive anticoagulation, and has the benefit of reducing length of stay by more than 50% to 3.2 days in an uncomplicated case.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8868982      PMCID: PMC484513          DOI: 10.1136/hrt.76.3.238

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  9 in total

1.  Diagnosis of acute myocardial infarction by MONICA and FINMONICA diagnostic criteria in comparison with hospital discharge diagnosis.

Authors:  P Palomäki; H Miettinen; H Mustaniemi; S Lehto; K Pyörälä; M Mähönen; J Tuomilehto
Journal:  J Clin Epidemiol       Date:  1994-06       Impact factor: 6.437

2.  Avoiding interpretive pitfalls when assessing arrhythmia suppression after myocardial infarction: insights from the long-term observations of the placebo-treated patients in the Cardiac Arrhythmia Pilot Study (CAPS)

Authors:  C M Pratt; A Hallstrom; P Theroux; D Romhilt; J Coromilas; J Myles
Journal:  J Am Coll Cardiol       Date:  1991-01       Impact factor: 24.094

3.  A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group.

Authors:  P W Serruys; P de Jaegere; F Kiemeneij; C Macaya; W Rutsch; G Heyndrickx; H Emanuelsson; J Marco; V Legrand; P Materne
Journal:  N Engl J Med       Date:  1994-08-25       Impact factor: 91.245

4.  A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators.

Authors:  D L Fischman; M B Leon; D S Baim; R A Schatz; M P Savage; I Penn; K Detre; L Veltri; D Ricci; M Nobuyoshi
Journal:  N Engl J Med       Date:  1994-08-25       Impact factor: 91.245

5.  Long-term angiographic and clinical outcome after implantation of a balloon-expandable stent in the native coronary circulation. Palmaz-Schatz Stent Study Group.

Authors:  M P Savage; D L Fischman; R A Schatz; P S Teirstein; M B Leon; D Baim; S G Ellis; E J Topol; J W Hirshfeld; M W Cleman
Journal:  J Am Coll Cardiol       Date:  1994-11-01       Impact factor: 24.094

6.  Changing incidence and management of abrupt closure following coronary intervention in the new device era.

Authors:  R E Kuntz; R Piana; R M Pomerantz; J Carrozza; R Fishman; M Mansour; R D Safian; D S Baim
Journal:  Cathet Cardiovasc Diagn       Date:  1992-11

7.  Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty.

Authors:  U Sigwart; J Puel; V Mirkovitch; F Joffre; L Kappenberger
Journal:  N Engl J Med       Date:  1987-03-19       Impact factor: 91.245

8.  Long-term outcome of women compared with men after successful coronary angioplasty.

Authors:  M R Bell; D E Grill; K N Garratt; P B Berger; B J Gersh; D R Holmes
Journal:  Circulation       Date:  1995-06-15       Impact factor: 29.690

9.  Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance.

Authors:  A Colombo; P Hall; S Nakamura; Y Almagor; L Maiello; G Martini; A Gaglione; S L Goldberg; J M Tobis
Journal:  Circulation       Date:  1995-03-15       Impact factor: 29.690

  9 in total
  2 in total

Review 1.  Aspirin in patients with coronary artery disease: is it simply irresistible?

Authors:  G V Nair; C J Davis; M E McKenzie; D R Lowry; V L Serebruany
Journal:  J Thromb Thrombolysis       Date:  2001-04       Impact factor: 2.300

2.  C-reactive protein and fibrin clot strength measured by thrombelastography after coronary stenting.

Authors:  Rolf P Kreutz; Janelle Owens; Jeffrey A Breall; Deshun Lu; Elisabeth von der Lohe; Islam Bolad; Anjan Sinha; David A Flockhart
Journal:  Blood Coagul Fibrinolysis       Date:  2013-04       Impact factor: 1.276

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.